Track Record

  • At the beginning of 2017, AgriMetis raised $23.5M Series B capital.
  • Innovating sustainable crop protection products through leading edge discovery, development and delivery methods.
  • Acidophil co-founded Agrimetis in 2014 with a series A raise of $10M.
  • PGT developed tools, that contribute to a better understanding of the inherent complexity of human, animal, plant and microbiological genomes.
  • PGT was formed following a £1 million seed investment from Wellcome Trust, and then raised £3.5 million Series A from Auriga, Beringea and Compass Genetics (which includes Acidophil), before raising a further £5 million Series B from Syngenta Ventures and Series A investors.
  • PGT with Acidophil’s help is in the process of commercializing its technologies by licensing out intellectual property and sales to research tool and molecular diagnostic companies.
  • Cost-competitive solutions to produce renewable intermediate chemicals via a bio-based or a fully biological approach using any one of a number of specifically tailored microorganisms that can utilise low cost feedstocks.
  • Zuvasyntha was founded by the merger of Biosyntha and Zuvachem

  • Arginetix (later Corridor Pharmaceuticals) was formed to develop therapeutics arginase inhibitors to treat respiratory and cardiac indications.
  • Arginetix raised $2 million seed funds from Acidophil, MedImmune Ventures and Quaker BioVentures and Red Abbey Venture Partners, then attracted a $7 million Series A financing.
  • Arginetix merged with Immune Control to form Corridor Pharmaceuticals, which was subsequently acquired by AstraZeneca.